Overview

A Study in Schizophrenia Patients

Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
An inpatient/outpatient study to see if LY2140023 is better than placebo in acutely ill patients with schizophrenia.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Risperidone